Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels

Clinical Positron Imaging (Netherlands)

Volumn 3, Issue 6, 2000, Pages 231-236

  Jimenez Bonilla J ^a   Maldonado, A ^a   Morales, S ^b   Salud, A ^b   Zomeno M ^a   Roman J ^c   Belon, J ^d   Moya, F ^a  

^a Instituto Tecnologico PET   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c Clinica Nuevo Parque   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Clinical impact; CT; Diagnostic accuracy; Diagnostic techniques; FDG PET; NMR; Ovarian carcinoma; Recurrence; Tumor markers

Indexed keywords

EID: 0001611265     PISSN: 10950397     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1095-0397(01)00053-X     Document Type: Article

References (19)

1. B Feig D Berger M Fuhrman The M.D. Anderson surgical oncology 2000 Lippincott Philadelphia
2. S.A Cannistra Cancer of the ovary N. Engl. J. Med. 329 1993 1550 1559
3. W.J Hoskins C.A Perez R.C Young Principles and practice of gynecologic oncology 1992 Lippincott Philadelphia
4. S.E Brooks Preoperative evaluation of patients with suspected ovarian cancer Gynecol Oncol 55 3 Pt2 1994 S80 S90
5. L.G Strauss P.S Conti The applications of PET in clinical oncology J. Nucl. Med. 32 1991 623 628
6. C.K Hoh C Schiepers M.A Seltzer PET in oncology will it replace the other modalities? Semin. Nucl. Med. 27 1997 94 106
7. J.A Richter A Maldonado L Rubio PET en oncologı́a. PET. Tomografı́a molecular. Fundamentos y aplicaciones 1993 Eseuve Madrid
8. J.L Carreras A Maldonado C Trampal La PET en oncologı́a ginecológica. Libro del año de Obstetricia y Ginecologı́a 1998 Saned Madrid
9. N Avril J Dose F Janicke Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluro-2-deoxy-D-glucoe J. Natl. Cancer Inst 88 1996 1204 1209
10. V.J Lowe J.W Fletcher L Gobar Prospective investigation of positron emission tomography in lung nodules J. Clin. Oncol. 16 1998 1075 1084
11. B.Y Karlan R Hawkins C Hoh Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma Gynecol Oncol. 51 1993 175 181
12. O Warburg The metabolism of tumors 1931 Richard R Smith New York
13. P Madariaga M.J Pérez A Jiménez Utilidad de la 18FDG-PET en la localización de lesiones tumorales tras elevación de marcadores Oncologı́a 21 1998 213 218
14. A Maldonado F Sancho R Pérez Value of FDG-PET in the therapeutic management of recurrent ovarian cancer experience in 31 patients Clin. Pos. Imag. 2 1999 321
15. C Trampal A Maldonado F Sancho Cuesta S Morales A Llunch C Señor de Urı́a Papel de la tomografı́a por emisión de positrones (PET) en la sospecha de recidiva tumoral ante la elevación sérica de marcadores tumorles Rev. Esp. Med. Nuclear 19 2000 279 287
16. W.B Eubank D.A Mankoff U.P Schmiedl Imaging of oncologic patients benefit of combined CT and FDG PET in the diagnosis of malignancy AJR Am. J. Roentgenol 171 1998 1103 1110
17. P.H Wang R.S Liu Y.F Li H.T Ng C.G Yuan Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent primary serous peritoneal carcinoma an initial report Gynecol. Oncol. 77 2000 44 47
18. R.A Kubik-Huch W Dorffler G.K Von Schulthess Value of (18F)-FDG positron emission tomography, computed tomography and magnetic resonance imaging in diagnosis primary and recurrent ovarian carcinoma Eur. Radiol. 10 2000 761 767
19. E Steichen-Gersdorf H.H Gallion D Ford Familial site-specific ovarian cancer is linked to BRCA1 on 17q12–21 Am. J. Hum. Genet. 55 1994 870 875